| 刘佩 彭晓燕 逄明杰 郭菲菲 孙向荣 公衍玲 徐珞.Ghrelin,内脂素和护骨素在Ⅱ型糖尿病发病机制中的作用研究[J].现代生物医学进展英文版,2016,16(18):3423-3426. |
| Ghrelin,内脂素和护骨素在Ⅱ型糖尿病发病机制中的作用研究 |
| Effect of Ghrelin, Visfatin and Osteoprotegerin in the Pathogenesis of TypeⅡDiabetes Mellitus |
| |
| DOI： |
| 中文关键词: 护骨素 内脂素 生长激素释放肽 2 型糖尿病 代谢综合症 |
| 英文关键词: Osteoprotegerin Visfatin Ghrelin Type 2 diabetes mellitus Metabolic Syndrome |
| 基金项目:国家自然科学基金项目(81470815，31071014，81100260，81270460，81300281，81500414)；
山东省优秀中青年科学家科研奖励基金项目（BS2014YY009）；青岛市科技局项目（13-1-4-170-jch，14-2-3-3-nsh） |
|
| Hits: 847 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨护骨素（osteoprotegerin）、内脂素（visfatin）和生长激素释放肽（ghrelin）在2 型糖尿病（T2DM）代谢综合症发病机制
中的作用。方法：采集受试者血清血样116 例（39 例2 型糖尿病代谢综合症较轻组；48 例2 型糖尿病代谢综合症较重组；29 例正
常对照组）。采用酶催法检测血糖和血脂。采用ELISA 法测定护骨素、内脂素、生长激素释放肽和胰岛素水平。结果：与对照组相
比，糖尿病代谢综合症较轻组患者护骨素和内脂素水平显著增高，生长激素释放肽水平显著降低（P<0.05）。此外，2 型糖尿病兼代
谢综合症较重组患者体内护骨素和内脂素水平明显高于较轻组患者（P<0.05）。采用ROC 曲线研究标记物最佳剂量值。2 型糖尿
病兼代谢综合症较重组患者护骨素（1.06 ng/mL）、内脂素（32.27 ng/mL）和生长激素释放肽（33.65 pg/mL）可分别表现出76 %、92
%和39.1 %灵敏性及41 %、69.2 %和62.9 %特异性。在研究的这些参数中，内脂素是预测糖尿病患者兼代谢综合症的有效指标
（P<0.05）。结论：护骨素、内脂素和生长激素释放肽可能作用于糖尿病患者的发病过程。内脂素是预测糖尿病患者兼代谢综合症的
有效指标。 |
| 英文摘要: |
| Objective:To investigate the possible role of osteoprotegerin, visfatin and ghrelin in the pathogenesis of the metabolic
syndrome (MetS) among type 2 diabetes mellitus (T2DM).Methods:Blood was taken from116 cases (39 T2DMwith less serious MetS,
48 T2DM with more serious MetS, 29 normal controls). Blood glucose and lipid level were detected by enzymatic method.
Osteoprotegerin, visfatin, ghrelin and insulin levels were assessed by ELISA method.Results:Compared with the control group,
osteoprotegerin and visfatin levels were significantly higher in patients with T2DM with less serious MetS, ghrelin levels were
significantly lower (P<0.05). In addition, osteoprotegerin and visfatin levels were significantly higher in type 2 diabetes with more serious
MetS than those with less serious metabolic syndrome (P<0.05). The optimal dose values of the investigated markers were assessed by
ROC curve. In type 2 diabetes patients with more serious metabolic syndrome, osteoprotegerin (1.06 ng/mL), visfatin (32.27 ng/mL) and
ghrelin (33.65 pg/mL) exhibited sensitivity of 76 %, 92 % and 39.1 %; specificity of 41 %, 69.2 % and 62.9 %. Among the studied
parameters, visfatin is an effective indicator for the prediction of diabetes with metabolic syndrome (P<0.05).Conclusion:Osteoprotegerin, visfatin and ghrelin might act on the pathogenesis of diabetes. Visfatin is a valid predictor of diabetes with metabolic
syndrome. |
|
View Full Text
View/Add Comment Download reader |
| Close |
